6:53 PM
 | 
Dec 07, 2017
 |  BC Week In Review  |  Company News  |  Deals

Akouos licenses gene therapy tech from Massachusetts Eye and Ear

Newco Akouos Inc. (Boston, Mass.) acquired an exclusive license to a vector platform from Massachusetts Eye and Ear (Boston, Mass.) and Lonza Group Ltd. (SIX:LONN) to develop gene therapies for hearing and balance disorders. The license includes sublicensing rights.

The platform includes 40,000 in silico-designed ancestral adeno-associated virus (AAV) vectors developed by Luk Vandenberghe at Massachusetts Eye and Ear.

Concurrently, Akouos raised $7.5...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >